Excited to announce that Calla Lily Clinical Care will be attending the PODD Conference in Boston next week! Our Principal Scientist Andrew Lewis and co-founder Lara Zibners will be showcasing our innovative vaginal drug delivery platform and its numerous applications beginning with pregnancy and fertility, and exploring new partnership opportunities. Stay tuned for updates on …

I had the great honour of meeting with Linda Griffith, Professor of Biological and Mechanical Engineering, and MacVicar Fellow at Massachusetts Institute of Technology, where she leads the MIT Center for Gynepathology Research. I’ve long been inspired by Professor Griffith’s groundbreaking work, and now, with our progress and dedicated team & lab resources in place, …

Our team of experts at Calla Lily Clinical Care understands the challenges, questions, and emotions that come with the path to pregnancy. That’s why we are proud to highlight Tommy’s charity Tommy’s is a leading UK charity doing amazing work researching pregnancy complications and baby loss, including miscarriage, stillbirth, and premature birth. The charity’s work …

Did you know that 3 years ago the UK became the first country in the world to recommend vaginally-administered 400mg progesterone to reduce miscarriages? It is estimated that 150,000 women each year in the UK should be taking progesterone, dubbed the “pregnancy hormone”, to reduce the risk of suffering a miscarriage. For those who didn’t …

Thank you to BBC Science Focus for mentioning Calla Lily Clinical Care’s drug delivery device in their article. “One of the current problems with vaginally-inserted medications is they often result in drug leakage and increased discharge. However, one company, @Calla Lily Clinical has developed a new leak-free vaginal drug delivery platform. This device is simple …